The natural sweetener metabolite steviol inhibits the proliferation of human osteosarcoma U2OS cell line

Oncology Letters

Volumn 15, Issue 4, 2018, Pages 5250-5256

  Chen, Jun Ming ^a   Zhang, Jue ^b   Xia, Yong Mei ^a   Wang, Xiao Xia ^a   Li, Jian ^b  

^a JIANGNAN UNIVERSITY   (China)

^b JIANGSU INSTITUTE OF NUCLEAR MEDICINE   (China)

Author keywords

Apoptosis; Osteosarcoma; Steviol; Steviol glycoside; U2OS

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; SWEETENING AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LD50; OSTEOSARCOMA;

EID: 85042642857     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2018.7962     Document Type: Article

References (32)

1. Renwick AG and Tarka SM: Microbial hydrolysis of steviol glycosides. Food Chem Toxicol 46 (Suppl 7): S70-S74, 2008.
2. Purkayastha S, Pugh G Jr, Lynch B, Roberts A, Kwok D and Tarka SM Jr: In vitro metabolism of rebaudioside B, D, and M under anaerobic conditions: Comparison with rebaudioside A. Regul Toxicol Pharmacol 68: 259-268, 2014.
3. Toskulkac C, Chaturat L, Temcharoen P and Glinsukon T: Acute toxicity of stevioside, a natural sweetener, and its metabolite, steviol, in several animal species. Drug Chem Toxicol 20: 31-44, 1997.
4. Moons N, De Borggraeve W and Dehaen W: Stevioside and steviol as starting materials in organic synthesis. Curr Organic Chem 16: 1986-1995, 2012.
5. EFSA Panel on Food Additives and Nutrient Sources (ANS): Scientific Opinion on safety of steviol glycosides for the proposed uses as a food additive. EFSA Journal 8: 1537, 2010.
6. Ge Y, Wang Y, Pang L, Zhang L, Zhai Y and Zhou H: Proliferation, apoptosis, and invasion effects of mistletoe alkali on human osteosarcoma U2OS in vitro. Int Surg: April 25, 2016 (Epub ahead of print).
7. Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev 40: 523-532, 2014.
8. Zhang J, Zhu X, Li H, Li B, Sun L, Xie T, Zhu T, Zhou H and Ye Z: Piperine inhibits proliferation of human osteosarcoma cells via G2/M phase arrest and metastasis by suppressing MMP-2/-9 expression. Int Immunopharmacol 24: 50-58, 2015.
9. Ottaviani G and Jaffe N: The Epidemiology of Osteosarcoma. In: Pediatric and Adolescent Osteosarcoma. Jaffe N, Bruland OS and Bielack S (eds.) Springer US, pp3-13, 2010.
10. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.
11. Rejniak KA, Lloyd MC, Reed DR and Bui MM: Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials. Med Hypotheses 85: 348-354, 2015.
12. Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-Where do we stand? A state of the art review. Cancer Treat Rev 40: 523-532, 2014.
13. Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: State of the art. Cancer Metastasis Rev 28: 247-263, 2009.
14. Hattinger CM, Pasello M, Ferrari S, Picci P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs 15: 615-634, 2010.
15. Janeway KA and Grier HE: Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol 11: 670-678, 2010.
16. Muñoz A, Alfaro J, Pardo N, García-Miguel P, Quintero V, Gros L, Melero C, Antuña MJ, Ocete G, de Las Heras J, et al: Long-term results of the Spanish Protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremities in children. Clin Transl Oncol 11: 387-392, 2009.
17. Zhao S, Lu N, Chai Y and Yu X.: Rapamycin inhibits tumor growth of human osteosarcomas. J Buon 20: 588-594, 2015.
18. Lu M, Huang W, Bao N, Zhou G and Zhao J: The flavonoid ampelopsin inhibited cell growth and induced apoptosis and G0/G1 arrest in human osteosarcoma MG-63 cells in vitro. Pharmazie 70: 388-393, 2015.
19. Lee DH, Qi J, Bradner JE, Said JW, Doan NB, Forscher C, Yang H and Koeffler HP: Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Int J Cancer 136: 2055-2064, 2015.
20. Maugg D, Rothenaigner I, Schorpp K, Potukuchi HK, Korsching E, Baumhoer D, Hadian K, Smida J and Nathrath M: New small molecules targeting apoptosis and cell viability in osteosarcoma. PLoS One 10: e0129058, 2015.
21. Meng ZJ, Wu N, Liu Y, Shu KJ, Zou X, Zhang RX, Pi CJ, He BC, Ke ZY, Chen L, et al: Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling. Oncol Rep 34: 1388-1396, 2015.
22. Wang Y, Ji Y, Hu Z, Jiang H, Zhu F, Yuan H and Lou H: Riccardin D induces cell death by activation of apoptosis and autophagy in osteosarcoma cells. Toxicol in Vitro 27: 1928-1936, 2013.
23. Boonkaewwan C, Ao M, Toskulkao C and Rao MC: Specific immunomodulatory and secretory activities of stevioside and steviol in intestinal cells. J Agric Food Chem 56: 3777-3784, 2008.
24. Yuajit C, Muanprasat C, Gallagher AR, Fedeles SV, Kittayaruksakul S, Homvisasevongsa S, Somlo S and Chatsudthipong V: Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease. Biochem Pharmacol 88: 412-421, 2014.
25. Takasaki M, Konoshima T, Kozuka M, Tokuda H, Takayasu J, Nishino H, Miyakoshi M, Mizutani K and Lee KH: Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds. Bioorg Med Chem 17: 600-605, 2009.
26. Shen J, Park HS, Xia YM, Kim GS and Cui SW: The polysaccharides from fermented Ganoderma lucidum mycelia induced miRNAs regulation in suppressed HepG2 cells. Carbohydr Polym 103: 319-324, 2014.
27. Plumb JA: Cell sensitivity assays: The MTT assay. In: Cancer Cell Culture Springer, pp165-169, 2004.
28. Li X, Wu WK, Sun B, Cui M, Liu S, Gao J and Lou H: Dihydroptychantol A, a macrocyclic bisbibenzyl derivative, induces autophagy and following apoptosis associated with p53 pathway in human osteosarcoma U2OS cells. Toxicol Appl Pharmacol 251: 146-154, 2011.
29. Cappadone C, Stefanelli C, Malucelli E, Zini M, Onofrillo C, Locatelli A, Rambaldi M, Sargenti A, Merolle L, Farruggia G, Graziadio A, et al: p53-dependent and p53-independent anticancer activity of a new indole derivative in human osteosarcoma cells. Biochem Biophys Res Commun 467: 348-353, 2015.
30. Diehl JA: Cycling to cancer with cyclin D1. Cancer Biol Ther 1: 226-231, 2002.
31. Martin S, Reutelingsperger C, McGahon AJ, Rader JA, van Schie RC, LaFace DM and Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182: 1545-1556, 1995.
32. Zinkel S, Gross A and Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13: 1351-1359, 2006.